News

Results from the ADvance trial, a Phase 2 study investigating the safety of deep brain stimulation (DBS) for the treatment of Alzheimer’s disease (AD), lead researchers to believe the treatment is safe and well-tolerated in patients. DBS targets a specific brain structure involved in memory pathways. The research paper, “Bilateral deep…

Scientists from the Center for Nanoparticle Research at South Korea’s Institute for Basic Science (IBS), in collaboration with researchers at Seoul National University, have developed mitochondria-targeting ceria nanoparticles, a potential therapeutic candidate for mitochondrial oxidative stress and seen as one of the possible pathogenic pathways involved in the onset of Alzheimer’s…

A collaboration between researchers at two universities in Halifax, Nova Scotia, in Canada has resulted in the discovery of an innovative, non-invasive diagnostic agent for Alzheimer’s disease, where before such a definitive diagnosis would have been possible only from a brain autopsy. However, new findings by research teams led by…

Researchers have discovered that a genetic elimination of peripheral immune cell populations leads to a more rapid development of amyloid brain plaques (which are present in Alzheimer’s patients), worsening of neuroinflammation, and dysfunction of microglial activity. The study, “The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function,”…

Takeda Pharmaceutical Company and partner Zinfandel Pharmaceuticals announced the completion of patient enrollment in the TOMMORROW Phase 3 Clinical Trial, one of the largest studies ever to be executed in mild cognitive impairment and Alzheimer’s disease (AD). Previous research has shown that individuals who develop mild cognitive impairment (MCI) are…

Researchers at Atlanta’s Emory University, under the guidance of neurologist Dr. Allan Levey, are studying the lineage of a specific family whose members are exceptionally prone to the development of late-onset Alzheimer’s disease in the search for new causes, such as novel genetic mutations, biomarkers, and brain changes. The ongoing…

A critical but vulnerable brain region seems to be the first area disturbed by late onset Alzheimer’s disease, and to be a region more essential for preserving cognitive function in later life than previously thought, according to a review, “The Locus Coeruleus: Essential for Maintaining Cognitive…

Researchers at the Johns Hopkins Bloomberg School of Public Health have developed “mini-brains” that may present a more accurate and effective way of testing new drugs for many neurological disorders, such as Alzheimer’s disease. These human cell-derived structures, which represent an existing new alternative to animal testing, were recently discussed in a…

Scientists have discovered the anti-cancer drug bexarotene may target the first step in the toxic chain activity that leads to the death of brain cells, paving the way to new Alzheimer’s therapies. The study, conducted by an international team of researchers from the University of Cambridge in England, Lund University in…

Researchers have discovered that the skeleton surrounding the nucleus of brain cells is dysfunctional in Alzheimer’s disease patients, which could lead to neuronal death. The study, “Lamin Dysfunction Mediates Neurodegeneration in Tauopathies,” was published in Current Biology. The lamin nucleoskeleton that surrounds the nucleus of cells is important in the…